Trump’s ‘Two Out, One In’ Regulatory Policy May Apply to Some FDA Guidance image

Regulatory Affairs Professionals Society (RAPS), February 6, 2017
Zachary Brennan, quoting Rachel E. Sachs (Academic Fellow Alumna)


Read the full article

From the article:

As far as what existing regulations if repealed would be considered part of the “two out” part of the EO, OMB notes, “Any existing regulatory action that imposes costs and the repeal or revision of which will produce verifiable savings may qualify.”

Rachel Sachs, an associate professor of law at Washington University in St. Louis, said she thinks the guidance "significantly restricts" and "walks back" the reach of the EO, particularly as it exempts big classes of regulations required by law and appreciates that regulations may be deregulatory in nature so the costs and issuance of such regulations will be considered accordingly.

Read more here!

bioethics fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation